Affiliation:
1. National & local Joint engineering research center of High-throughput drug screening technology State Key Laboratory of Biocatalysis and Enzyme Engineering Hubei Key Laboratory of Biotechnology of Chinese Traditional Medicine College of Health Science and Engineering Hubei University Wuhan 430062 China
2. Gansu Herbal Medicine Planting Co., Ltd. Lanzhou 730102 China
3. Shenzhen Institue of Geriatrice Shenzhen 518020 China
Abstract
AbstractThree neolignan glycosides, including a new compound (7S,8R)‐dihydro‐3′‐hydroxy‐7‐(4‐hydroxy‐3‐methoxyphenyl)‐1′‐benzofuranpropanol‐9‐O‐β‐D‐xylopyranoside (1), were isolated from the root of Nothopanax davidii. Their structures were determined by extensive spectroscopic analyses, particularly NMR, HR‐ESI‐MS, and ECD experiments, and the absolute configuration of 2 was first definitively determined. The anti‐tumor activity was assessed on four tumor cells by MTT assay, the anti‐inflammatory activity was determined by inhibition of NO production in LPS reduced RAW264.7 cells, and the interaction with iNOS was predicted by molecular docking. At the dose of 100 μM, the three neolignan glycosides showed no cytotoxic activity against HepG2, HCT116, HeLa and A549 human tumor cells, but significantly inhibited LPS induced NO generation in RAW264.7 cells with inhibition rates of 31.53 %, 23.95 %, and 20.79 %, respectively, showing weak anti‐inflammatory activity, possibly due to their binding to key residues of iNOs involved in inhibitor binding.
Subject
Molecular Biology,Molecular Medicine,General Chemistry,Biochemistry,General Medicine,Bioengineering
Cited by
1 articles.
订阅此论文施引文献
订阅此论文施引文献,注册后可以免费订阅5篇论文的施引文献,订阅后可以查看论文全部施引文献